-
MedAdvisor aces FY24
Friday | Aug 30 2024STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
-
Enhertu gets PBS listing
Friday | Aug 30 2024AUSTRALIANS with a newly defined type of metastatic breast cancer, HER2-low, will now have access to a life-prolonging drug under the PBS from 01 Sep.
-
Overdose aware
Friday | Aug 30 2024AHEAD of International Overdose Awareness Day tomorrow, the Pharmaceutical Society of Australia (PSA) is highlighting new challenges faced by pharmacists, including the rise of nitazines around Australia.
-
Save on travel
Friday | Aug 30 2024PHARMACISTS can take advantage of Pointrs’ free 30-day trial to explore more than 5,000 travel deals.
-
IV shortage fix
Friday | Aug 30 2024A global shortage of IV fluids, driven by surging demand and manufacturing constraints, has prompted urgent action by the Commonwealth, states and territories.
-
Superbug rates
Friday | Aug 30 2024RESEARCHERS from Flinders University and SAHMRI are urging more careful antibiotic management in aged care facilities to protect residents from antibiotic-resistant bacteria, or superbugs.
-
Dispensary Corner 30 Aug 24
Friday | Aug 30 2024AS THE 2024 Paralympic Games kick off, Bupa is going for gold… in wellness!
-
PD for Fri 30 Aug 2024
Friday | Aug 30 2024MedAdvisor aces FY24, PSA is overdose aware, Govt addresses IV fluid shortage, Enhertu gets PBS listing, and more
-
Mixed results at Priceline
Thursday | Aug 29 2024WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
-
Approval for Sandoz’s drugs
Thursday | Aug 29 2024SANDOZ ANZ has received regulatory approval for two denosumab biosimilars, Jubbonti, for treating osteoporosis in post-menopausal women and, Wyost, for cancer-related bone disease.
PARTNER SITES
to top